Need Help?

Longitudinal copy number variation analysis from plasma DNA of head and neck cancer patients under re-radiotherapy

Recurrent locally advanced head and neck cancer (HNC) patients, receiving re-radiotherapy (re-RT), are presented with short progression-free (PFS) and overall survival. Hence, biomarkers predicting therapy failure are urgently needed. We analyzed copy number variations (CNVs) in blood plasma of HNC patients collected before, during and after re-RT. Detectable CNVs after five and ten fractions of re-irradiation as well as at the end of re-RT were associated with short PFS. Furthermore, we found that CNV kinetics in longitudinally collected plasma reflected therapy response and could detect disease progression in advance of radiographic tumor assessments.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD50000000233 Illumina NovaSeq 6000 191
Publications Citations
Early circulating tumor DNA changes predict outcomes in head and neck cancer patients under re-radiotherapy.
Int J Cancer 156: 2025 853-864
0